SLC18A2 and Parkinson disease: This neuroprotective action involves regulating vesicular monoamine transporter 2 (VMAT2), reducing cytoplasmic dopamine accumulation and preventing the formation of neurotoxic reactive oxygen species, a mechanism particularly relevant in conditions like methamphetamine abuse and neurodegenerative diseases such as Parkinson’s [38].